Study design considerations: Conducting global clinical trials in early Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 14, Issue 4, 2010, Pages 312-314

  Schindler, R J ^a  

^a PFIZER INC   (United States)

Author keywords

Access; Early Alzheimer's disease; Global clinical trials; Harmonization; Regulatory requirements; Scales; Standardization

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BIOASSAY; CLINICAL ASSESSMENT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; HUMAN; LINGUISTICS; MEDICAL RESEARCH; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REIMBURSEMENT; STANDARDIZATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; ECONOMICS; GOVERNMENT REGULATION; HEALTH; INTERNATIONAL COOPERATION; LEGISLATION AND JURISPRUDENCE; PROCEDURES; SEVERITY OF ILLNESS INDEX; STANDARD; TREATMENT OUTCOME;

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; GLOBAL HEALTH; GOVERNMENT REGULATION; HUMANS; INTERNATIONAL COOPERATION; REFERENCE STANDARDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951791154     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-010-0071-4     Document Type: Article

References (16)

1. Alzheimer's Disease Facts and Figures, 2007. Available at: http://www.alz.org/alzheimer's-disease-facts-figures.asp
2. Sabbagh M. Drug development for Alzheimer's disease: Where are we now and where are we headed? The American Journal of Geriatric Pharmacotherapy. 2009;7(3):167-185.
3. Verhey FR, Houx P, Van Lang N, Huppert F, Stoppe G, Saerens J. Bohm P, de Vreese L, Nordlund A, DeDeyn PP. Neri M, Pena-Casanova J, Wallin A, Bollen E, Middelkoop H, Nargeot MC, Puel, M. Fleischman UM, Jolles J. Cross-national comparison and validation of the Alzheinier's Disease Assessment Scale: results form the European Harmonization Project for Instruments in Dementia (EURO-HARPID). In J Geriatr Psychiatry 2004; 19: 41-50.
4. Chiu HFK, Lam LCW. Relevance of outcome measures in different cultural groups - does one size fit all? International Psychogeriatrics 2007, 19:3, 457-466.
5. Hobart JC, Cano S, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6: 1094-1105
6. Black R, Greenberg, B, Ryan JM, Posner H. Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carillo M, Stern Y. Scales as outcome measures for Alzheimer's disease. Alzheimers Dement 2009 Jul;5(4):324-339
7. Jonsson B. time for a common standard for cost-effectiveness in Europe? Eur Health Econ 2006, 7: 223-224.
8. European Medicines Agency,(EMEA) Committee for Medicinal Products for Human Use (CHMP), Doc. Ref EMEA/CHMP/EWP/692702/2008. Reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU-Population. http://www.emea.europa.eu/pdfs/human/ewp/69270208en.pdf
9. Broich, K, Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Int Psychogeriatr. 2007 Jun;19(3):509-524
10. Sampaio, C, Biomarkers in clinical trials of Alzheimer's disease: what is expected from regulatory agencies? J Nutr Health Agiong. 2009 Apr;13(4):339-340
11. Mueller SG, Weiner MW, Thai LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dement, 2005 Jul; 1(1): 55.66.
12. Weiner MW. Alzheimer's Disease Neuroimaging Initiative. Int. Conf. Alzheinier's Disease. Chicago IL., 2008, July
13. Petersen RC, Jack CR. Imaging and biomarkers in early Alzheimer's disease and Mild Cognitive Impairment. Clin Pharm Therapeutics 2009, 86(4): 438-441.
14. Ivinson AJ, Lane R, May PC, Hosford DA, Canillo MC, Siemera ER. Partnership between academia and industry for drug discovery in Alzheimer's disease. Alzheimer'a Dement 2008 Mar;4(2):80-90
15. Becker RE, Greig NH. Alzheiiner's disease drug development in 2008 and beyond: problems and opportunities. Cure. Alz. Res., 2008, 5, 346-357
16. Anand R. Barriers to Alzheimer disease drug discovery and drug development in the pharnsaceutical industry. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1.S33-9.